关于全资子公司参与广东联盟双氯芬酸等药品 接续采购拟中选的公告 证券代码：002872 证券简称：ST 天圣 公告编号：2025-062 天圣制药集团股份有限公司 二、此次拟入围对公司的影响 本次湖北天圣、湖南天圣上述产品拟中选广东联盟双氯芬酸等药品接续采购， 若后续签订相关采购合同并实施，将有利于扩大相关产品的销售范围，提高市场 占有率及品牌影响力。 三、风险提示 上述拟中选产品相关采购合同尚未签订，后续事项及对公司的影响程度尚存 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司(以下简称"公司")之全资子公司湖北天圣药业 有限公司（以下简称"湖北天圣"）、湖南天圣药业有限公司（以下简称"湖南 天圣"）参加了广东联盟双氯芬酸等药品接续采购工作。根据广东省药品交易中 心于 2025 年 10 月 10 日发布的《广东省药品交易中心关于公示广东联盟双氯芬 酸等药品接续采购拟中选结果的通知》，湖北天圣产品浓氯化钠注射液、盐酸克 林霉素注射液、葡萄糖注射液、氯化钠注射液，湖南天圣产品注射用头孢硫脒、 注射用头孢唑肟钠拟中选本次接续采购。现将相 ...

Core Viewpoint - ST Tian Sheng's subsidiaries, Hubei Tian Sheng and Hunan Tian Sheng, have participated in the procurement process for various pharmaceutical products, which may enhance their market presence and brand influence [1] Group 1: Procurement Participation - Hubei Tian Sheng and Hunan Tian Sheng are involved in the Guangdong Alliance procurement for drugs including concentrated sodium chloride injection, clindamycin hydrochloride injection, glucose injection, sodium chloride injection, and injectable cefoperazone and cefazolin sodium [1] Group 2: Potential Impact - The selection of these products for procurement is expected to expand the sales range and increase market share [1] - However, it is important to note that the procurement contracts have not yet been signed, leading to uncertainty regarding the subsequent impact on the company [1]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-061 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易 所股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司" 或"天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 2、公司于 2025 年 9 月 12 日收到中国证券监督管理委员会重庆监管局（以 下简称"重庆证监局"）出具的《行政处罚事先告知书》（处罚字（2025）4 号）（以下简称"《告知书》"），《告知书》中指出公司披露的年度报告财 务指标存在虚假记载行为，根据《深圳证券交易所股票上市规则》相关规定， 公司股票交易自 2025 年 9 月 15 日起被叠加实施其他风险警示。 1、控股股东刘群涉嫌侵占公司资金，由于刘群部分涉案财物已扣押、冻结、 查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交易所股 票上市规则》相关规定，公司股 ...

Core Viewpoint - Tian Sheng Pharmaceutical Group held an investor relations meeting to address various inquiries regarding its performance and future strategies, focusing on governance, sales expenses, share repurchase, and innovation in drug development [1][2][3][4] Group 1: Governance and Risk Warning - Tian Sheng Pharmaceutical's stock was placed under risk warning due to fund misappropriation by its controlling shareholder, with the company having repaid the principal and interest by April 2021. However, it received a notice of administrative penalty from the Chongqing Securities Regulatory Bureau in September 2025, leading to continued risk warnings [1] - The company is committed to enhancing corporate governance and internal control management to meet the conditions for lifting the risk warning [1] Group 2: Sales Strategy - As a pharmaceutical manufacturer, Tian Sheng Pharmaceutical incurs high sales expenses, exceeding 20% of revenue, due to the need to establish nationwide sales channels and adapt sales strategies to expand market reach [2] Group 3: Share Repurchase and Market Value Management - The company plans to utilize its own funds or special loans for share repurchase to enhance investor confidence and maintain market value, ensuring compliance with legal requirements and committing to timely information disclosure [3] Group 4: Innovation and Export - Tian Sheng Pharmaceutical has over 300 approved drug varieties, covering multiple therapeutic areas, and is focused on continuous research and development, production excellence, and sales expansion to achieve sustainable growth and turnaround from losses [4] - Currently, the company does not engage in drug exports but emphasizes strict adherence to quality control regulations [4]

证券代码： 002872 证券简称：ST 天圣 天圣制药集团股份有限公司 投资者关系活动记录表 编号：2025-002 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 √ 业绩说明会 | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 下午 2025 9 25 (周四) 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事张娅 | | 员姓名 | 2、财务总监王开胜 | | | 3、董事会秘书王琴 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问公司占用问题有没有彻底解决，是不是行政处罚满 | | | 一年公司就符合摘帽条件？谢谢 | | | 尊敬的投资者，您 ...

Group 1 - The core point of the article is that ST Tian Sheng's stock is currently trading at 5.05 yuan, reflecting a decline of 3.07% and is in a state of breaking the issue price [1] - ST Tian Sheng was listed on the Shenzhen Stock Exchange's SME board on May 19, 2017, issuing 53 million shares at a price of 22.37 yuan per share, raising a total of 1.186 billion yuan [1] - The net amount raised after deducting issuance costs was 1.079 billion yuan, with specific allocations including 573 million yuan for GMP technology transformation of oral solid preparations, 199 million yuan for non-PVC soft bag large-volume injection GMP technology transformation, 209 million yuan for the Tian Sheng (Chongqing) modern pharmaceutical logistics headquarters, and 98.265 million yuan for the drug research and development center [1] Group 2 - The total issuance costs amounted to approximately 107 million yuan, which included 67.736 million yuan paid to Huaxi Securities for sponsorship and underwriting fees, 22.526 million yuan for legal fees to Beijing Mingshui Law Firm, and 5.08 million yuan for audit and verification fees to Beijing Xinghua Accounting Firm [1] - The issuance cost per share was 2.02 yuan [1]

Core Viewpoint - ST Tian Sheng has been penalized for financial fraud involving off-balance sheet funds, resulting in a total fine of 4.39 million yuan for the company and 22 responsible individuals [3][4]. Financial Fraud Details - The financial fraud methods employed by ST Tian Sheng primarily revolved around an "off-balance sheet fund pool," where the company inflated project costs and procurement expenses to siphon funds into a hidden pool [4]. - In the annual reports for 2017 and 2018, ST Tian Sheng inflated total profits by 175 million yuan and 47.9 million yuan, respectively, while also reducing profits by 82.58 million yuan and 19.09 million yuan through inflated procurement costs [4]. - The total inflated profits for 2017 and 2018 amounted to 92.20 million yuan and 28.82 million yuan, representing 30.21% and 20.61% of the reported profits for those years [4]. Undisclosed Related Transactions - The undisclosed related transactions for 2017 and 2018 reached 481 million yuan and 48.63 million yuan, accounting for 15.08% and 1.49% of the net assets at the end of those periods [5]. - Notably, after the company's listing, the undisclosed related transactions amounted to 329 million yuan, exceeding 15% of the most recent audited net assets [5]. Regulatory Actions - The Chongqing Securities Regulatory Bureau imposed penalties on ST Tian Sheng for failing to disclose related transactions and for false reporting in the 2017 and 2018 annual reports, including a warning and a fine of 600,000 yuan [6]. - Key individuals, including Liu Qun, received significant fines and market bans, with Liu Qun facing a total fine of 900,000 yuan and a lifetime ban from the securities market [6]. Legal Consequences for Executives - Liu Qun, the actual controller of ST Tian Sheng, was sentenced to 19 years in prison for multiple crimes, including bribery and embezzlement, along with fines totaling 2 million yuan and the confiscation of personal assets worth 8 million yuan [7]. Internal Governance Issues - The financial fraud case highlights severe deficiencies in the company's internal governance, leading to a risk warning status since April 2019, with the stock name changed to "ST Tian Sheng" [8]. - The company's recent performance has been poor, with a reported revenue of 232 million yuan in the first half of 2025, a year-on-year decline of 17.49%, and a net loss of 36.71 million yuan [8].

Core Points - ST Tian Sheng (002872) approved a guarantee for its wholly-owned subsidiary Hubei Tian Sheng to apply for bank credit [1] - Hubei Tian Sheng signed a 10 million yuan loan agreement with Yunxian Rural Commercial Bank, secured by self-owned factory and invention patent [1] - ST Tian Sheng provides joint liability guarantee for the loan, covering principal, interest, and other aspects for a period of three years after the loan term [1] Financial Summary - As of June 30, 2025, Hubei Tian Sheng reported total assets of 224.9254 million yuan [1] - The total balance of external guarantees provided by the company and its subsidiaries is 131.3034 million yuan, with no overdue or litigated guarantees [1]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-059 天圣制药集团股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开 的第六届董事会第十三次会议审议通过了《关于为全资子公司提供担保的议案》。 同意公司为全资子公司湖北天圣药业有限公司（以下简称"湖北天圣"）向银行 申请授信提供担保事项，董事会授权公司经营层在担保额度范围内负责本次担保 相关的协议及文件的签署；在授信额度内，全资子公司向银行申请的具体贷款金 额以银行实际审批的最终结果为准，具体担保金额及保证期间按实际签订合同约 定 执 行 。 具 体 内 容 详 见 公 司 于 2025 年 8 月 28 日 刊 载 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的《关于为全资子公司提供担保的公告》（公告 编号：2025-051）。 二、本次担保的进展情况 近日，湖北天圣与湖北郧县农村商业银行股份有限公司（简称"郧县 ...

关于参加重庆辖区 2025 年投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002872 证券简称：ST 天圣 公告编号：2025-060 天圣制药集团股份有限公司 本次活动将于 2025 年 9 月 25 日（星期四）下午 15:00-17:00 举行，投资者 可以登录"全景路演"平台（http://rs.p5w.net）进入公司互动平台参与交流。 为进一步做好投资者关系管理工作，加强与投资者的沟通交流，天圣制药 集团股份有限公司（以下简称"公司"）将参加由重庆证监局指导、重庆上市 公司协会联合深圳市全景网络有限公司举办的"重庆辖区上市公司 2025 年投资 者网上集体接待日暨半年度业绩说明会活动"（以下简称"本次活动"）。 2025 年 9 月 19 日 届时，公司相关董事及高级管理人员将参加本次活动，并通过网络在线交 流形式，就投资者所关心的问题，与投资者进行"一对多"形式的在线交流， 欢迎广大投资者积极参与。 特此公告。 天圣制药集团股份有限公司董事会 ...